---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-060033"
form_type: "8-K"
ticker: null
cik: "0001651311"
company_name: "Merus N.V."
filed_at: "2024-03-06T23:59:59+00:00"
generated_at: "2026-06-05T02:42:36.329195+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Merus enters $56M upfront collaboration with Gilead for trispecific antibody programs; potential $1.5B milestones

## Summary
- Gilead pays $56M upfront for rights to Merus' Triclonics platform; up to two more programs at $28M each.
- Total potential milestones up to ~$1.5B across three programs; tiered royalties mid-single to low double digits.
- Gilead purchases 452,527 shares at $55.2454/share (~$25M) in private placement; no transfer for set period.
- Merus may elect 50/50 profit-loss share for third program after first IND filing instead of milestones/royalties.
- Agreement covers at least two preclinical programs; Gilead has exclusive option per program to license and commercialize.

## SEC filing metadata
- accession: 0001193125-24-060033
- form_type: 8-K
- cik: 0001651311
- company_name: Merus N.V.
- filed_at: 2024-03-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1651311/000119312524060033/0001193125-24-060033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1651311/000119312524060033/d815831d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-060033
- JSON: https://secwatch.observer/filing/0001193125-24-060033.json
- Plain text: https://secwatch.observer/filing/0001193125-24-060033.txt

## Key facts
- Material Agreements
  Merus N.V. entered into Collaboration Agreement with Gilead Sciences, Inc. valued at $56 million (effective 2024-03-05).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Gilead Sciences, Inc.
  - Value: $56 million
  - Effective: 2024-03-05
  source text: On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651311/000119312524060033/0001193125-24-060033-index.htm
- Material Agreements
  Merus N.V. entered into Share Subscription Agreement with Gilead Sciences, Inc. (effective 2024-03-05).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Gilead Sciences, Inc.
  - Effective: 2024-03-05
  source text: On March 5, 2024, we entered into a collaboration, option and license agreement (“Collaboration Agreement”) and Share Subscription Agreement (the “Subscription Agreement”) with Gilead Sciences, Inc. (“Gilead”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1651311/000119312524060033/0001193125-24-060033-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.